Biopharmaceutical Report III Issue6_April 2015 Featured Story of Korean Pharma: Hanwha confirms abandoning bid for Dow Chemical basic...

Biopharmaceutical Report II Issue6_April 2015 Astellas (TYO:4503)/Medivation's (NASDAQ:MDVN) Phase II TERRAIN study topline data on...

Biopharmaceutical Report I Issue6_April 2015 Spark Therapeutics' (NASDAQ:ONCE) subretinal gene therapy injection of SPK-RPE65, is likely...

Biopharmaceutical Report II Issue5_February 2015 • Logistic complications create high demand for the expertise of comparator suppliers •...

Biopharmaceutical Report I Issue5_February 2015 • Phase II signals encouraging for positive Phase III translation • Capsaicin as...

Biopharmaceutical Report II Issue4_November 2014 • Remsima use may be forced ahead of Remicade, but not Humira or Enbrel • ...

Biopharmaceutical Report I Issue4_November 2015 • Enrollment criteria expanded mid-trial to reflect shifting treatment landscape • ...

Biopharmaceutical Report III Issue3_September 2014 Over the last decade or so, I have observed a tempering of what was once a large and...

Biopharmaceutical Report II Issue3_September 2014 • Superiority to standard therapy bodes well for approvals • Regulators may require...

Biopharmaceutical Report I Issue3_September 2014 • Historical responses meaningful, but approvability based on transfusion changes...